Fortitude Group Announces Legacy Life Science Acquisition

Life Science Investing News

Fortitude Group Inc.,(FRTD) CEO Thomas Parilla announced the company’s acquisition of Legacy Life Science, the company’s first medical division.

Fortitude Group Inc.,(FRTD) CEO Thomas Parilla announced the company’s acquisition of Legacy Life Science, the company’s first medical division.

As quoted in the press release:

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia).

Click here to read the full Fortitude Group Inc.,(FRTD) press release.

The Conversation (0)
×